Yep, pretty ridiculous when you consider that B-OM alone will likely be the market leader in an indication that has the potential to save, by the math in the last IPIX PR, $700,000,000 a year in additional inpatient expenses incurred when suffering from SOM in just the US. I dont know what that translates to in revenue, but I think it is safe to say that it is more than $76M dollars of market cap.